Product Name: Pazopanib
Synonyms: Pazopanib(GW786034);5-(4-((2,3-diMethyl-3,3a-dihydro-2H-indazol-6-yl)(Methyl)aMino)pyriMidin-2-ylaMino)-2-MethylbenzenesulfonaMide;5-[(4-{[(2,3-diMethyl-2H-indazol-6-yl)Methyl]aMino}pyriMidin-2-yl)aMino]-2-Methylbenzene-1-sulfonaMide;5-({4-[(2,3-diMethyl-2H-indazol-6-yl)(Methyl)aMino]pyriMidin-2-yl}aMino)-2-MethylbenzenesulfonaMide 5-(4-(N-(2,3-diMethyl-2H-indazole-6-yl)- N-MethylaMino)pyriMidine-2-ylaMino)-2-MethylbenzenesulfonaMide;Votrient;5-[[4-[(2,3-DiMethyl-2H-indazol-6-yl)MethylaMino]-2-pyriMidinyl]aMino]-2-Methyl-benzenesulfonaMide;BenzenesulfonaMide, 5-[[4-[(2,3-diMethyl-2H-indazol-6-yl)MethylaMino]-2-pyriMidinyl]aMino]-2-Methyl-;Pazopanib base
CAS: 444731-52-6
MF: C21H23N7O2S
MW: 437.52
EINECS:
Product Categories: API;API;Intermediates & Fine Chemicals;Pharmaceuticals;HFC80010;Inhibitors
Mol File: 444731-52-6.mol

Pazopanib Chemical Properties
Melting point  285-289°C (dec.)
Boiling point  728.8±70.0 °C(Predicted)
density  1.40
Fp  359℃
storage temp.  Refrigerator
form  Yellow powder.
pka 10.19±0.60(Predicted)
Safety Information
Risk Statements  43-62/63
Safety Statements  36/37/39-28B
HS Code  29350090

Pazopanib Usage And Synthesis
product description Pazopanib is researched and developed by a GlaxoSmithKline ,it is a novel oral vascular generation inhibitor which may interfere stubborn tumor survival and new blood vessels generation growth needed .Targeting vascular endothelial growth factor receptor (VEGFR),it works by inhibiting angiogenesis of tumor blood supply.it is suitable for advanced renal cell carcinoma ( a discovery of cancer cells in the renal tubules), soft tissue sarcoma (STS), epithelial ovarian cancer and non-small cell lung cancer (NSCLC) treatment.
Minnesota Rochester, Mayo Clinical Research Clinical Research Center researches show that pazopanib (trade name Votrient) can effectively cure thyroid cancer,and can make half of the patients tumor volume reduced, compared to the commonly used drugs ,it is more prolonged stable ,and can be maintained for a considerable period of treatment, the drug has the highest response rate in treatment of thyroid cancer so far.
The US Food and Drug Administration (FDA) approved on October 19, 2009 that pazopanib (trade name Votrient) is listed ,the sixth approved drug treatment of kidney cancer since 2005. In 2009, approximately 49,000 patients were diagnosed with renal cell carcinoma, 11,000 patients died of the disease.
June 15, 2010, pazopanib, EU conditionally approved it for advanced renal cell cancer and first-line treatment in patients with previously received cytokine therapy. Once the European Commits to give final marketing authorization for this drug, GlaxoSmithKline will have exclusive marketing rights pazopanib for ten years.
The efficacy of the treatment of advanced renal cell carcinoma In order to investigate the efficacy of molecule targeting drug tyrosine kinase inhibitor pazopanib which inhibist the angiogenesis in patients with advanced renal cell carcinoma, People's Liberation Army General Hospital, in June 2006 to May 2007, the participation of pazopanib in patients with advanced renal cell carcinoma randomized clinical drug trials of outpatient 14 cases, were divided into pazopanib group (n = 10) and placebo group ( 4 cases), were treated with pazopanib 800mg/d and placebo after 12 weeks of treatment duration, according to the results of CT scan before and after medication , efficacy was determined .
The results showed that the reduced average ratios of measurable disease focus of pazopanib and placebo patients were 27.6%,-2.8% (P A clinical trail study phase I showed that compared with placebo, pazopanib can reduce the risk of death and tumor progression by 54%. Overall,in the product group of patients ,disease progression-free survival (PFS) mean survival time was 9.2 months ,in the placebo group was 4.2 months. In previously treated patients who had not received in this product group average survival time was 11.1 months in the placebo group was 2.8 months; previously received cytokine therapy patients, pazopanib group survived an average of 7.4 months, the placebo group was 4.2 months.

Product Name: Pazopanib
Synonyms: Pazopanib(GW786034);5-(4-((2,3-diMethyl-3,3a-dihydro-2H-indazol-6-yl)(Methyl)aMino)pyriMidin-2-ylaMino)-2-MethylbenzenesulfonaMide;5-[(4-{[(2,3-diMethyl-2H-indazol-6-yl)Methyl]aMino}pyriMidin-2-yl)aMino]-2-Methylbenzene-1-sulfonaMide;5-({4-[(2,3-diMethyl-2H-indazol-6-yl)(Methyl)aMino]pyriMidin-2-yl}aMino)-2-MethylbenzenesulfonaMide 5-(4-(N-(2,3-diMethyl-2H-indazole-6-yl)- N-MethylaMino)pyriMidine-2-ylaMino)-2-MethylbenzenesulfonaMide;Votrient;5-[[4-[(2,3-DiMethyl-2H-indazol-6-yl)MethylaMino]-2-pyriMidinyl]aMino]-2-Methyl-benzenesulfonaMide;BenzenesulfonaMide, 5-[[4-[(2,3-diMethyl-2H-indazol-6-yl)MethylaMino]-2-pyriMidinyl]aMino]-2-Methyl-;Pazopanib base
CAS: 444731-52-6
MF: C21H23N7O2S
MW: 437.52
EINECS:
Product Categories: API;API;Intermediates & Fine Chemicals;Pharmaceuticals;HFC80010;Inhibitors
Mol File: 444731-52-6.mol

Pazopanib Chemical Properties
Melting point  285-289°C (dec.)
Boiling point  728.8±70.0 °C(Predicted)
density  1.40
Fp  359℃
storage temp.  Refrigerator
form  Yellow powder.
pka 10.19±0.60(Predicted)
Safety Information
Risk Statements  43-62/63
Safety Statements  36/37/39-28B
HS Code  29350090

Pazopanib Usage And Synthesis
product description Pazopanib is researched and developed by a GlaxoSmithKline ,it is a novel oral vascular generation inhibitor which may interfere stubborn tumor survival and new blood vessels generation growth needed .Targeting vascular endothelial growth factor receptor (VEGFR),it works by inhibiting angiogenesis of tumor blood supply.it is suitable for advanced renal cell carcinoma ( a discovery of cancer cells in the renal tubules), soft tissue sarcoma (STS), epithelial ovarian cancer and non-small cell lung cancer (NSCLC) treatment.
Minnesota Rochester, Mayo Clinical Research Clinical Research Center researches show that pazopanib (trade name Votrient) can effectively cure thyroid cancer,and can make half of the patients tumor volume reduced, compared to the commonly used drugs ,it is more prolonged stable ,and can be maintained for a considerable period of treatment, the drug has the highest response rate in treatment of thyroid cancer so far.
The US Food and Drug Administration (FDA) approved on October 19, 2009 that pazopanib (trade name Votrient) is listed ,the sixth approved drug treatment of kidney cancer since 2005. In 2009, approximately 49,000 patients were diagnosed with renal cell carcinoma, 11,000 patients died of the disease.
June 15, 2010, pazopanib, EU conditionally approved it for advanced renal cell cancer and first-line treatment in patients with previously received cytokine therapy. Once the European Commits to give final marketing authorization for this drug, GlaxoSmithKline will have exclusive marketing rights pazopanib for ten years.
The efficacy of the treatment of advanced renal cell carcinoma In order to investigate the efficacy of molecule targeting drug tyrosine kinase inhibitor pazopanib which inhibist the angiogenesis in patients with advanced renal cell carcinoma, People's Liberation Army General Hospital, in June 2006 to May 2007, the participation of pazopanib in patients with advanced renal cell carcinoma randomized clinical drug trials of outpatient 14 cases, were divided into pazopanib group (n = 10) and placebo group ( 4 cases), were treated with pazopanib 800mg/d and placebo after 12 weeks of treatment duration, according to the results of CT scan before and after medication , efficacy was determined .
The results showed that the reduced average ratios of measurable disease focus of pazopanib and placebo patients were 27.6%,-2.8% (P A clinical trail study phase I showed that compared with placebo, pazopanib can reduce the risk of death and tumor progression by 54%. Overall,in the product group of patients ,disease progression-free survival (PFS) mean survival time was 9.2 months ,in the placebo group was 4.2 months. In previously treated patients who had not received in this product group average survival time was 11.1 months in the placebo group was 2.8 months; previously received cytokine therapy patients, pazopanib group survived an average of 7.4 months, the placebo group was 4.2 months.